Brokerages Set Biogen Inc. (NASDAQ:BIIB) Price Target at $205.04

Analysts maintain 'Hold' rating on the biotech company's stock.

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

Biogen Inc. (NASDAQ:BIIB) has earned a consensus 'Hold' rating from 27 research firms covering the stock, with an average 12-month price target of $205.04. Fifteen analysts have rated the stock as 'Hold' while twelve have issued a 'Buy' recommendation.

Why it matters

Biogen is a major player in the biotechnology industry, particularly in the development of therapies for neurological and neurodegenerative diseases. The company's stock performance and analyst sentiment can provide insights into the broader biotech market and investor sentiment around Biogen's pipeline and commercial products.

The details

The average 12-month price target of $205.04 represents a potential upside of around 7% from the stock's current trading price. Several analysts have recently adjusted their price targets and ratings on Biogen, with BMO Capital Markets lifting its target to $196 and maintaining a 'Market Perform' rating, while TD Cowen boosted its target to $215 and kept a 'Buy' recommendation. The Goldman Sachs Group also reiterated a 'Buy' rating on the stock.

  • Biogen reported its latest quarterly earnings on February 6, 2026.

The players

Biogen Inc.

A multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases, headquartered in Cambridge, Massachusetts.

BMO Capital Markets

An investment bank and financial services company that has provided a 'Market Perform' rating and $196 price target for Biogen.

TD Cowen

An investment bank that has boosted its price target for Biogen to $215 and maintained a 'Buy' recommendation.

The Goldman Sachs Group

An investment bank that has reiterated a 'Buy' rating on Biogen's stock.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.